Nightingale Health and Innoquest Diagnostics have joined forces to enable access to Nightingale Health's blood analysis technology in Southeast Asia. Under the agreement, Nightingale Health will collaborate with Innoquest to deploy its technology to perform the blood test in Singapore and launch Nightingale Health's comprehensive and high-quality blood testing services by the end of the first half of 2024. The blood test will be offered by Innoquest to healthcare providers in Singapore and regionally through the other companies within the Pathology Asia group.

This important agreement fulfills the first of Nightingale Health's business targets for the financial year 2023-2024. The agreement achieves the target of forming an international commercial contract with a healthcare industry partner with significant reference and contract value since it makes the company's blood analysis technology available through a partner with a significant market share in a large region.